DRG Epidemiology's coverage of bipolar disorder comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of bipolar disorder for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's bipolar disorder forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of bipolar disorder?
- Of all people diagnosed with bipolar disorder, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of bipolar disorder over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the United States, Europe and Japan. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following bipolar disorder patient populations:
- Total Lifetime Prevalent Cases - BPD I by Manic Episode
- Total Lifetime Prevalent Cases by Generalized Anxiety Comorbidity
- Total Lifetime Prevalent Cases by Severity
- Bipolar Disorder Total Lifetime Prevalent Cases
- Diagnosed Lifetime Prevalent Cases Drug-Treatment subpopulation(s)
- Total Lifetime Prevalent Cases by Major Depressive Episode Comorbidity
- Total Lifetime Prevalent Cases Diagnosis subpopulation(s)
Note: coverage may vary by country and region.
- Bipolar Disorder - Epidemiology - Mature Markets Data
- Key Findings
- Prevalence of Bipolar Disorder per 1,000 Among Adults in 2017 and 2037
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Bipolar Disorder over the Next Twenty Years
- Number of Additional Prevalent Cases of Bipolar Disorder Incurred Over the Period 2017-2037 Across the Countries Under Study
- Analysis of the Prevalent Cases of Bipolar Disorder in 2017 by Diagnosed and Drug-Treated Status
- Analysis of the Prevalent Cases of Bipolar Disorder in 2017 by Subtype
- Key Findings
- Epidemiology Data
- Total Lifetime Prevalence
- Diagnosed Prevalence
- Comorbid Depression
- Comorbid Generalized Anxiety Disorder
- Bipolar Mania
- Subthreshold Bipolar Disorder
- Drug-Treated Prevalence
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Bipolar Disorder
- Studies Excluded from the Analysis of Bipolar Disorder
- Risk/Protective Factors
- Risk/Protective Factors for Bipolar Disorder
- Literature Review
Author(s): Wouter van der Pluijm, MPH; Abey John, MPH
Wouter van der Pluijm is a Senior Epidemiologist at Decision Resources Group and joined in 2014.
Wouter holds an M.P.H. in Epidemiology from the University of Michigan. Prior to joining DRG, Wouter worked for the Washtenaw County Public Health Department on the epidemiology and public health surveillance teams, studying West Nile virus, as well as depression and drug abuse in the county.
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.
Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.